VITL Raises Multiple Rounds to Scale Personalized Nutrition and Wellness Platform
VITL, the London‑based personalized nutrition and wellness company, has successfully raised multiple rounds of funding since its launch in 2015, securing capital from a mix of institutional backers, angel investors, and equity crowdfunding supporters to fuel its vision of tailored health solutions that combine technology with bespoke supplement formulation. The company’s mission — to make personalized health insights and vitamin products more accessible — has evolved into a compelling investment narrative as VITL continues to integrate data‑driven diagnostics, AI‑assisted recommendations, and direct‑to‑consumer delivery models.
In one of its earliest funding milestones, VITL raised £550,000 in late 2017 in a seed round that was led by the £100 million Angel CoFund, a UK government‑supported investment vehicle focused on early‑stage companies, underscoring confidence from sophisticated backers in VITL’s personalized nutrition approach. This round also saw participation from prominent individual investors including Alex Chesterman, the founder of Zoopla, and Simon Duffy, the CEO of Bulldog Skincare, reflecting broad belief in VITL’s potential to disrupt the nutritional supplement space with data‑driven products.
Following this initial round, VITL expanded its investor base and tapped into the power of community capital through equity crowdfunding. In 2018, the company launched a campaign on Crowdcube and rapidly approached its £1 million target, ultimately closing with more than £1 million raised from nearly 480 investors. This campaign was noteworthy not only for exceeding its funding goal but also for broadening ownership, allowing everyday investors to participate alongside seasoned angels and institutional backers. The funds raised through Crowdcube were earmarked for growth marketing, team expansion, and product development, as VITL sought to scale its personalized nutrition offerings and deepen its technological capabilities.
In 2022, VITL further strengthened its financial foundation with a £6.2 million investment round led by Ornament Health AG, a Swiss health‑technology investor that has collaborated with VITL on strategic health solutions. This significant cash infusion was positioned to help the company expand its retail presence, enter new markets, and enhance its marketing reach, responding to rising consumer demand for personalized health products and data‑driven nutritional insights. Alongside Ornament Health, other high‑profile investors joined the round, including Richard Pennycook, former CEO of The Co‑operative Group, whose involvement brought deep expertise in scaling consumer brands. These global investors signaled confidence in VITL’s ability to compete in the wellness and nutrition sector while maintaining a strong data‑centric foundation.
Across its funding history, VITL has attracted support from a diverse roster of investors that reflect both its technological promise and market appeal. In addition to Ornament Health AG and Angel CoFund, the company’s backers have included founders and executives from innovative consumer businesses such as LoveFilm and Bloom & Wild, demonstrating cross‑sector enthusiasm for personalized wellness solutions. Venture capital and growth firms like Redbus Ventures and Samos Investments have also been associated with VITL’s earlier rounds, reinforcing its ability to attract institutional capital alongside individual believers.
The capital raised to date has supported VITL’s expansion beyond digital consultations to incorporate at‑home testing options including DNA and blood tests, enabling deeper insight into individual health profiles. As part of its growth trajectory, the company has also established retail partnerships with major UK chains, bringing its personalized vitamin packs to broader audiences and enhancing its offline presence. VITL’s strategy bridges online‑first diagnostics and offline retail distribution, a dual approach that resonates with investors looking for scalable health and wellness models.
VITL’s founders and leadership have emphasized the strategic importance of these funding rounds in enabling sustained innovation. The funds have underpinned the development of machine‑learning algorithms for personalization, the expansion of production and logistics capabilities, and the acceleration of international growth plans. By linking personalized nutrition data with consumer needs, VITL aims to differentiate itself from generic supplement brands and position its platform as an integrated health solution for a global audience.
Looking ahead, VITL’s funding journey illustrates the company’s commitment to scaling personalized wellness technology and building a community of investors aligned with its mission. The strategic injections of capital — from government‑backed funds, angel networks, high‑profile consumer leaders, and international health tech investors — have collectively laid a financial foundation for continued innovation. With a strong investor base and evolving product suite, VITL is poised to expand its reach, refine its technology, and continue shaping the future of personalized health and nutrition.
